IOL Chemicals and Pharmaceuticals · NSE: IOLCP · BSE: 524164
Q3 FY22 results · Oct–Dec 2021
IOL Chemicals and Pharmaceuticals reported revenue from operations of ₹555.14 crore (up 8.2% from Q3 FY21) and net profit of ₹40.07 crore (down 65.1% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 555.14 | 513.01 | +8.2% | 537.88 | +3.2% |
| Other income | 8.88 | 7.81 | +13.7% | 10.51 | −15.5% |
| Total income | 564.02 | 520.82 | +8.3% | 548.39 | +2.9% |
| Profit before tax | 54.67 | 153.63 | −64.4% | 41.62 | +31.4% |
| Net profit for the period | 40.07 | 114.81 | −65.1% | 30.84 | +29.9% |
| EPS, basic (₹) | 6.82 | 19.54 | −65.1% | 5.26 | +29.7% |
| Net margin (%) | 7.2 | 22.4 | 5.7 |
Standalone
- Filed with BSE
- 04 Feb 2022, 19:33 IST
- Board meeting
- 04 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Audited
- Source
- XBRL filing on BSE